Updated Breyanzi® labeling: Reduced post-infusion monitoring period, reduced post-treatment driving restrictions, and REMS removal make
Breyanzi accessible to more patients. Learn more >
Breyanzi is the one CAR T to bring hope for remission to more patients
Select an indication to find efficacy and safety data, dosing and administration
information, and resources for you and your patients.
R/R Large B-Cell Lymphoma (LBCL)
3L+ Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
3L+ Follicular Lymphoma (FL)
3L+ Mantle Cell Lymphoma (MCL)
*Please see the full indications and limitations of use further below.
†Treatment process includes leukapheresis, manufacturing, administration, and adverse event monitoring.1
3L, third-line; CAR, chimeric antigen receptor; R/R, relapsed or refractory.
Reference
- Breyanzi [package insert]. Summit, NJ: Bristol-Myers Squibb Company; 2025.